Hyaluronidase, an enzyme that degrades hyaluronic acid, has attracted considerable attention across diverse industries for its applications in drug permeation enhancement and dermal filler removal. With the growing subcutaneous (SC) injection market, research on hyaluronidase-based drug delivery systems has become increasingly active. This study aims to predict future development directions of hyaluronidase subcutaneous injection applications through integrated analysis of publication, clinical trial, and patent data. A quantitative analysis was conducted on 283 hyaluronidase-related publications, 214 clinical trials, and 179 patents published from 2000 to August 2025, examining annual publication volumes, indications, drug types, and overall trends. Of all publications, research articles constituted the highest proportion, predominantly employed for drug delivery applications. Monoclonal antibodies and immunoglobulins represented the primary drug types. Clinical trials were evenly distributed across Phase I-III studies, with 42.1% completed. Patent filings increased around 2015, peaking in 2020, with the United States leading patent submissions. Hyaluronidase has exhibited a paradigm shift from an \"auxiliary enzyme\" to a \"essential drug delivery system.\" A sustained upward trajectory is anticipated along with the expanding biopharmaceutical market.